<?xml version="1.0" encoding="UTF-8"?>
<p>
 <bold>Policies on trial‐related physical, psychological, financial, and/or social harms</bold> should be negotiated with attention paid to individuals or groups who may be vulnerable, marginalized, and/or stigmatized.
 <fn id="dewb12283-note-1037">
  <label>37</label>
  <p>World Health Organization, op. cit. note 7.</p>
 </fn> When the protocol is being developed, researchers and stakeholders should discuss the responsibilities of local health institutions and the commitments of trial sponsors and implementers to finance trial‐related disability. The health systems in many countries in sub‐Saharan Africa are weak,
 <fn id="dewb12283-note-1038">
  <label>38</label>
  <p>Kirigia, J.M., &amp; Barry, S.P. (2008). Health challenges in Africa and the way forward. Int Arch Med. 1(1), 27.</p>
 </fn> with difficulties in meeting the care needs of COVID‐19 trial participants who may have trial‐related injuries, including social and psychological harm. The implications of positive viral antibody tests for individuals who participate in COVID‐19 vaccine trials should be discussed. Also, if COVID‐19 immunity passports become operational,
 <fn id="dewb12283-note-1039">
  <label>39</label>
  <p>Phelan, A.L. (2020). COVID‐19 immunity passports and vaccination certificates: scientific, equitable, and legal challenges. Lancet. 395(10237), 1595‐1598.</p>
 </fn> their implication for the overwhelming interest in research to acquire immunity will have to be considered, The implications for health insurance and third party trial‐related injuries also should be discussed.
</p>
